Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(33%)

Phase Distribution

Ph not_applicable
3
33%
Ph phase_1
1
11%
Ph phase_3
5
56%

Phase Distribution

1

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 3Large-scale testing
5(55.6%)
N/ANon-phased studies
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(5)
Terminated(3)
Other(1)

Detailed Status

Completed5
Terminated3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
62.5%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 35 (55.6%)
N/A3 (33.3%)

Trials by Status

terminated333%
unknown111%
completed556%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy

NCT00195637
unknownphase_3

IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency

NCT01992328
terminatednot_applicable

Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome

NCT00004833
completedphase_3

Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection

NCT00004422
terminatednot_applicable

Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy

NCT00004407
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT00195637Phase 1

Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy

Completed
NCT01992328Phase 3

IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency

Unknown
NCT00004833Not Applicable

Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome

Terminated
NCT00004422Phase 3

Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection

Completed
NCT00004407Not Applicable

Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy

Terminated
NCT00004682Not Applicable

Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis

Terminated
NCT00004744Phase 3

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis

Completed
NCT00004772Phase 3

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy

Completed
NCT00004286Phase 3

Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9